MARKET

MTVA

MTVA

MetaVia Inc
NASDAQ
2.890
+1.010
+53.72%
After Hours: 2.650 -0.24 -8.30% 19:59 05/20 EDT
OPEN
1.970
PREV CLOSE
1.880
HIGH
3.310
LOW
1.920
VOLUME
61.95M
TURNOVER
--
52 WEEK HIGH
19.03
52 WEEK LOW
0.9661
MARKET CAP
14.93M
P/E (TTM)
-0.4795
1D
5D
1M
3M
1Y
5Y
1D
MetaVia Announces Publication Of New Preclinical Research Supporting The Anti-Fibrotic Potential Of Vanoglipel In the Journal Biomolecules & Therapeutics
Benzinga · 18h ago
MetaVia cites preclinical study showing vanoglipel reduces liver fibrosis in MASH
PUBT · 18h ago
MTVA Gains Weight, CODX Takes A Shot At Ebola, EDSA To Reveal New Data, BDTX On Watch
NASDAQ · 21h ago
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 1d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 1d ago
Why Agilysys Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
Benzinga · 1d ago
Fein Reiterates Buy on MetaVia, Keeps DA-1726-Driven Price Target Unchanged at $20
TipRanks · 2d ago
MetaVia Showcases Key Cardiometabolic Data at ADA 2026
TipRanks · 2d ago
More
About MTVA
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide 1, glucagon-dependent insulinotropic polypeptide receptor, and peptide YY.

Webull offers MetaVia Inc stock information, including NASDAQ: MTVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MTVA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MTVA stock methods without spending real money on the virtual paper trading platform.